0 10 Regulation Regulation NNP 11 13 of of IN 14 17 Fas Fas NNP 18 24 ligand ligand NN 25 35 expression expression NN 36 39 and and CC 40 44 cell cell NN 45 50 death death NN 51 53 by by IN 54 70 apoptosis-linked apoptosis-linked JJ 71 75 gene gene NN 76 77 4 4 CD 77 78 . . . 80 90 Programmed program VBN 91 95 cell cell NN 96 101 death death NN 102 104 is be VBZ 105 106 a a DT 107 114 process process NN 115 123 required require VBN 124 127 for for IN 128 131 the the DT 132 138 normal normal JJ 139 150 development development NN 151 153 of of IN 154 156 an an DT 157 165 organism organism NN 165 166 . . . 167 170 One one CD 171 173 of of IN 174 177 the the DT 178 182 best good JJS 183 193 understood understand VBN 194 203 apoptotic apoptotic JJ 204 212 pathways pathway NNS 213 219 occurs occur VBZ 220 222 in in IN 223 224 T t NN 225 236 lymphocytes lymphocyte NNS 237 240 and and CC 241 243 is be VBZ 244 252 mediated mediate VBN 253 255 by by IN 256 263 Fas/Fas Fas/Fas NNP 264 270 ligand ligand NN 271 272 ( ( ( 272 276 FasL FasL NNP 276 277 ) ) ) 278 289 interaction interaction NN 289 290 . . . 291 297 During during IN 298 305 studies study NNS 306 308 of of IN 309 318 apoptosis apoptosis NN 319 326 induced induce VBN 327 329 by by IN 330 331 T t NN 332 345 cell-receptor cell-receptor NN 346 356 engagement engagement NN 356 357 , , , 358 360 we we PRP 361 371 identified identify VBD 372 378 ALG-4F ALG-4F NNP 378 379 , , , 380 381 a a DT 382 391 truncated truncate VBN 392 402 transcript transcript NN 403 407 that that WDT 408 416 prevents prevent VBZ 417 418 T t NN 419 440 cell-receptor-induced cell-receptor-induced JJ 441 445 FasL FasL NNP 446 458 upregulation upregulation NN 459 462 and and CC 463 467 cell cell NN 468 473 death death NN 473 474 . . . 475 489 Overexpression overexpression NN 490 492 of of IN 493 504 full-length full-length JJ 505 510 ALG-4 alg-4 NN 511 518 induced induce VBD 519 532 transcription transcription NN 533 535 of of IN 536 540 FasL FasL NNP 541 544 and and CC 544 545 , , , 546 558 consequently consequently RB 558 559 , , , 560 569 apoptosis apoptosis NN 569 570 . . . 571 576 These these DT 577 584 results result NNS 585 593 indicate indicate VBP 594 598 that that IN 599 604 ALG-4 alg-4 NN 605 607 is be VBZ 608 617 necessary necessary JJ 618 621 and and CC 622 632 sufficient sufficient JJ 633 636 for for IN 637 641 FasL FasL NNP 642 652 expression expression NN 652 653 . . . 654 662 Fas/FasL Fas/FasL NNP 663 674 interaction interaction NN 675 684 initiates initiate VBZ 685 689 cell cell NN 690 695 death death NN 696 698 in in IN 699 703 many many JJ 704 709 other other JJ 710 717 systems system NNS 717 718 , , , 719 722 and and CC 723 726 its its PRP$ 727 740 dysregulation dysregulation NN 741 743 is be VBZ 744 745 a a DT 746 755 mechanism mechanism NN 756 758 by by IN 759 764 which which WDT 765 772 several several JJ 773 783 pathologic pathologic JJ 784 794 conditions condition NNS 795 800 arise arise VBP 800 801 . . . 802 815 Understanding understand VBG 816 819 the the DT 820 829 molecular molecular JJ 830 840 mechanisms mechanism NNS 841 843 of of IN 844 848 FasL FasL NNP 849 859 regulation regulation NN 860 865 could could MD 866 868 be be VB 869 873 very very RB 874 880 useful useful JJ 881 883 in in IN 884 895 elucidating elucidate VBG 896 899 how how WRB 900 905 these these DT 906 914 diseases disease NNS 915 922 develop develop VBP 923 926 and and CC 927 929 in in IN 930 941 identifying identify VBG 942 951 potential potential JJ 952 963 therapeutic therapeutic JJ 964 971 targets target NNS 971 972 . . .